Intas Pharmaceuticals Limited — Irinotecan Exporter Profile
Indian Pharmaceutical Exporter · #1 for Irinotecan · $15.1M export value · DGFT Verified
Intas Pharmaceuticals Limited is the #1 Indian exporter of Irinotecan with $15.1M in export value and 1,099 verified shipments. Intas Pharmaceuticals Limited holds a 35.8% market share in Irinotecan exports across 20 countries. The company exports 75 pharmaceutical products worth $372.3M across 19 therapeutic categories.
Intas Pharmaceuticals Limited — Irinotecan Export Profile: Buyers & Destinations
Where Does Intas Pharmaceuticals Limited Export Irinotecan?
| Country | Value | Shipments | Share |
|---|---|---|---|
| POLAND | $3.2M | 155 | 29.0% |
| NETHERLANDS | $2.6M | 187 | 23.5% |
| UNITED KINGDOM | $1.2M | 68 | 11.0% |
| ITALY | $682.9K | 49 | 6.2% |
| SOUTH AFRICA | $623.4K | 20 | 5.6% |
| SPAIN | $520.9K | 37 | 4.7% |
| BRAZIL | $517.5K | 18 | 4.7% |
| AUSTRALIA | $450.0K | 9 | 4.1% |
| CANADA | $437.7K | 10 | 4.0% |
| FRANCE | $381.5K | 11 | 3.4% |
Intas Pharmaceuticals Limited exports Irinotecan to 20 countries. The largest destination is POLAND accounting for 29.0% of Intas Pharmaceuticals Limited's Irinotecan shipments, followed by NETHERLANDS (23.5%) and UNITED KINGDOM (11.0%). These destinations reflect Intas Pharmaceuticals Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Irinotecan from Intas Pharmaceuticals Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| ALLOGA FRANCE | NETHERLANDS | $1.4M | 50 |
| ACCORD HEALTHCARE POLSKA SP. Z.O.O. | POLAND | $1.3M | 65 |
| ACCORD HEALTHCARE POLSKA SP. Z O.O. | POLAND | $1.0M | 38 |
| ACCORD UK | UNITED KINGDOM | $908.1K | 40 |
| BROCACEF NL : HUB | NETHERLANDS | $744.9K | 66 |
| TO THE ORDER | HUNGARY | $576.8K | 114 |
| ACCORD HEALTHCARE ITALIA SRL | ITALY | $471.6K | 30 |
| ACCORD HEALTHCARE POLSKA SP Z O O | POLAND | $423.4K | 28 |
| ACCORD HEALTHCARE PTY LTD | AUSTRALIA | $350.0K | 7 |
| ACCORD HEALTHCARE INC | CANADA | $319.4K | 7 |
Intas Pharmaceuticals Limited supplies Irinotecan to 70 buyers globally. The largest buyer is ALLOGA FRANCE (NETHERLANDS), followed by ACCORD HEALTHCARE POLSKA SP. Z.O.O. (POLAND) and ACCORD HEALTHCARE POLSKA SP. Z O.O. (POLAND). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Irinotecan Export Value and How Much Does Intas Pharmaceuticals Limited Contribute?
India exported $37.5M worth of Irinotecan through 2,905 shipments from 164 suppliers to 111 countries, serving 495 buyers globally. Intas Pharmaceuticals Limited contributes $15.1M to this total, accounting for 35.8% of India's Irinotecan exports. Intas Pharmaceuticals Limited ships Irinotecan to 20 countries through 70 buyers.
What Is the Average Shipment Value for Intas Pharmaceuticals Limited's Irinotecan Exports?
Intas Pharmaceuticals Limited's average Irinotecan shipment value is $13.7K per consignment, based on 1,099 shipments totaling $15.1M. The largest destination is POLAND (29.0% of Intas Pharmaceuticals Limited's Irinotecan exports).
How Does Intas Pharmaceuticals Limited Compare to Other Indian Irinotecan Exporters?
Intas Pharmaceuticals Limited ranks #1 among 164 Indian Irinotecan exporters with a 35.8% market share. The top 3 exporters are INTAS PHARMACEUTICALS LIMITED ($14.7M), FRESENIUS KABI ONCOLOGY LIMITED ($10.4M), EUGIA PHARMA SPECIALITIES LIMITED ($4.4M). Intas Pharmaceuticals Limited processed 1,099 shipments to 20 destination countries.
What Irinotecan Formulations Does Intas Pharmaceuticals Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| PHARMA DRUGS & MEDI IRINOTECAN INJ,20MG/ | $2.0M | 101 |
| PHARMA DRUG&MED:IRINOTECAN INJ,20MG/ML,2 | $202.7K | 8 |
| PHARMA DRUG&MED: IRINOTECAN INJ,20MG/ML, | $183.8K | 5 |
| PHARMA DRUGS & MEDI IRINOTECAN 20MG/ML,5 | $178.1K | 7 |
| PHARMA DRUGS & MEDI IRINOTECAN HCL INJ20 | $168.9K | 17 |
| PHARMA DRUG&MED:IRINOTECAN HCL INJ20MG/M | $165.1K | 11 |
| PHARMA DRUGS MEDI IRINOTECAN INJ 20MG ML 25ML ACCOR FRANCE AS PER INVOICE | $150.9K | 4 |
| PH.DRU.& MED.: IRINOTECAN HCL INJECTION | $150.0K | 3 |
| PHARMA DRUGS AND MEDI IRINOTAS 100 (20 MG/ML 5ML EACH ML CONTAINS IRINOTECAN HCL TRIHYDRATE 20MG.VLS | $150.0K | 3 |
| PHARMA DRUGS AND MEDI IRINOTECAN HYDROCHLORIDE INJ 20MG/ML,5ML AS PER INV | $144.2K | 4 |
Intas Pharmaceuticals Limited exports 604 distinct Irinotecan formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PHARMA DRUGS & MEDI IRINOTECAN INJ,20MG/ with 101 shipments worth $2.0M. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
Regulatory Requirements: Exporting Irinotecan to Key Markets
What Intas Pharmaceuticals Limited must comply with to export Irinotecan to its top destination countries
United Kingdom — MHRA
Approval Process
Post-Brexit UK Marketing Authorisation via national procedure. Separate from EU approval since January 2021.
Timeline: 12–15 months
GMP & Export Requirements
UK GMP compliance; MHRA inspection of manufacturing site
Manufacturer Import Authorisation (MIA) held by UK importer; Qualified Person (QP) batch release
Note: Post-Brexit: EU GMP certificates no longer automatically valid in UK. Separate MHRA recognition required.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Intas Pharmaceuticals Limited Compare to Nearest Irinotecan Exporters?
Exporters ranked immediately above and below #1 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | INTAS PHARMACEUTICALS LIMITED ★ | $14.7M | 1,099 | 20 | $13.4K |
| 2 | FRESENIUS KABI ONCOLOGY LIMITED | $10.4M | 670 | 24 | $15.6K |
| 3 | EUGIA PHARMA SPECIALITIES LIMITED | $4.4M | 88 | 10 | $50.0K |
Intas Pharmaceuticals Limited ranks #1 among 164 Indian Irinotecan exporters. Average shipment value of $13.4K compared to the market average of $228.7K. The closest competitors by value are FRESENIUS KABI ONCOLOGY LIMITED and EUGIA PHARMA SPECIALITIES LIMITED.
Which Indian Ports Ship Irinotecan Exports?
| Port | Shipments | % Share |
|---|---|---|
| DELHI AIR CARGO ACC (INDEL4) | 300 | 10.3% |
| SAHAR AIR | 296 | 10.2% |
| AHEMDABAD AIR ACC (INAMD4) | 252 | 8.7% |
| MUNDRA SEA (INMUN1) | 217 | 7.5% |
| SAHAR AIR CARGO ACC (INBOM4) | 207 | 7.1% |
| DELHI AIR | 205 | 7.1% |
| AHEMDABAD AIR | 205 | 7.1% |
| MUNDRA SEA | 152 | 5.2% |
What Other Oncology Products Does Intas Pharmaceuticals Limited Export?
Intas Pharmaceuticals Limited also exports these oncology products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Intas Pharmaceuticals Limited's Irinotecan Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Intas Pharmaceuticals. The Israel-Iran tensions have led to increased security risks in the Strait of Hormuz and the Red Sea–Suez Canal corridor, prompting major carriers to reroute shipments around the Cape of Good Hope. This detour has extended transit times by 10–20 days and raised freight rates by 40–50% on key India–Europe routes, impacting the cost-effectiveness and timeliness of exports. (livemint.com)
Conversely, the ongoing US-China trade tensions have opened avenues for Indian pharmaceutical companies to capture a larger share of the U.S. market. Intas's acquisition of UDENYCA® and the FDA's acceptance of its biosimilar applications position the company to leverage these opportunities effectively. However, compliance with the European Union's Falsified Medicines Directive (FMD) remains a critical factor for market access. Intas's proactive approach in securing partnerships and ensuring regulatory compliance underscores its commitment to maintaining and expanding its presence in the European market.
Intas Pharmaceuticals Limited — Regulatory Compliance & Quality Standards
Maintaining stringent regulatory compliance is paramount for Indian pharmaceutical exporters. Intas Pharmaceuticals has demonstrated a strong commitment to adhering to international quality standards, as evidenced by its successful acquisitions and partnerships that necessitate compliance with FDA, WHO, and EU Good Manufacturing Practices (GMP). The company's proactive engagement in regulatory processes, such as the FDA's acceptance of its Biologics License Application for DMB-3115, reflects its dedication to quality and compliance. (intaspharma.com) As global regulatory requirements continue to evolve, Intas's focus on quality assurance and compliance positions it favorably in the competitive pharmaceutical export market.
About Intas Pharmaceuticals Limited
Intas Pharmaceuticals Limited exports 75 products worth $372.3M. Beyond Irinotecan, top products include Ras, Mycophenolate, Tacrolimus, Apixaban, Ezetimibe. View the complete Intas Pharmaceuticals Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Irinotecan — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Irinotecan shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Intas Pharmaceuticals Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 1,120 individual customs records matching Intas Pharmaceuticals Limited exporting Irinotecan, covering 604 formulations to 20 countries via 70 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 111+ countries, 495+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Irinotecan Export Data from Intas Pharmaceuticals Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Intas Pharmaceuticals Limited's Irinotecan exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Intas Pharmaceuticals Limited
Full Company Profile →
75 products · $372.3M total trade · 19 categories
Irinotecan Stats
Company Overview
Top Products by Intas Pharmaceuticals Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Intas Pharmaceuticals Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Irinotecan. For current shipment-level data, contact TransData Nexus.